Company Description
Scribe Therapeutics is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.
While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions.
By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines.
Our focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD.
We are designing CRISPR-based genetic medicines to be well-tolerated, effective, durable, and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention, with the goal of broadly democratizing access to the cardioprotective effects of known genetic variants.
Our lead product candidate, STX-1150, utilizes ELXR, our highly engineered epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reductions without permanent genetic changes.
STX-1150 is a demonstration of moving towards our goal to transform practical therapeutic adherence and real-world medical outcomes for patients in the multibillion-dollar LDL-C lowering landscape.
We have secured regulatory clearance from the Australian Therapeutic Goods Administration, or TGA, for and initiated a first-in-human clinical trial of STX-1150 in Australia in up to 64 adults with elevated LDL-C and increased risk of ASCVD.
We anticipate reporting initial data from this trial, including safety, tolerability, and LDL-C-lowering activity, in the first half of 2027.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | Benjamin L. Oakes, Ph.D. |
Contact Details
Address: 1150 Marina Village Parkway Alameda, CA 94501 United States | |
| Phone | (510) 626-8587 |
| Website | scribetx.com |
Stock Details
| Ticker Symbol | SCTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1853921 |
| Employer ID | 82-2157847 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Oakes, Ph.D. | President, Chief Executive Officer and Director |
| Svetlana Lucas, Ph.D. | Chief Business Officer |
| David L. Parrot, M.B.A. | Chief Financial Officer |
| James Watson, M.B.A. | Director |
| Behzad Aghazadeh, Ph.D. | Director |
| Carl L. Gordon, Ph.D., CFA | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 12, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 6, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 9, 2026 | DRS | [Cover] Draft Registration Statement |
| Apr 2, 2021 | D | Notice of Exempt Offering of Securities |